NCT00093457View on ClinicalTrials.gov

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 10, 2004

Primary Completion Date

September 28, 2006

Study Completion Date

January 18, 2011

Conditions
Prostate Cancer
Interventions
DRUG

sorafenib tosylate

BAY 43-9006 given orally at 400 mg BID in a 28 day cycle

Trial Locations (7)

T2N 4N2

Tom Baker Cancer Centre - Calgary, Calgary

V1Y 5L3

British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna

V5Z 4E6

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program at London Health Sciences Centre, London

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

NCIC Clinical Trials Group

NETWORK